%PDF-1.6
%
58 0 obj
<>
endobj
60 0 obj
<>stream
2011-06-22T15:02:28Z
QuarkXPress(tm) 6.52
2011-09-26T14:13:21-04:00
2011-09-26T14:13:21-04:00
application/pdf
nlin
Layout 1
eCopy, Inc.
%%DocumentProcessColors: Black
%%EndComments
3.0
uuid:fcde8f98-6496-408f-9f52-d066ec738299
uuid:b1a1e483-7fe3-4c17-ad3b-f7417965d9ad
endstream
endobj
53 0 obj
<>
endobj
8 0 obj
<>]>>
endobj
54 0 obj
<>/ProcSet[/PDF/Text]/ExtGState<>>>/Type/Page>>
endobj
55 0 obj
<>/ProcSet[/PDF/Text]/ExtGState<>>>/Type/Page>>
endobj
56 0 obj
<>/ProcSet[/PDF/Text]/ExtGState<>>>/Type/Page>>
endobj
57 0 obj
<>/ProcSet[/PDF/Text]/ExtGState<>>>/Type/Page>>
endobj
7 0 obj
<>stream
/GS0 gs
1 g
0 783 0 0 re
f
q
/GS1 gs
0 0 0 0 k
50.5 490.794 493 242.399 re
f
Q
/GS1 gs
q
BT
/F1 1 Tf
8 0 0 8 64 727.7228 Tm
0 0 0 1 k
-0.01 Tc
0.01 Tw
(equation. Modification of Diet in Renal Disease Study Group. Ann In-)Tj
0 -1.2375 TD
-0.025 Tc
0.013 Tw
[(ter)-25(n Med 1999;130:461)50(-70.)]TJ
-1.20852 -1.3625 TD
-0.021 Tc
0.021 Tw
[(6.)-479(Bailie GR, Uhlig K, Levey AS. Clinical practice guidelines in nephrolo-)]TJ
1.20852 -1.2375 TD
-0.025 Tc
0.015 Tw
(gy: evaluation, classification, and stratification of chronic kidney disease.)Tj
T*
0.013 Tw
[(Phar)-25(macotherapy 2005;25:491)50(-502.)]TJ
-1.2094 -1.3625 TD
-0.022 Tc
0.022 Tw
[(7.)-478(Stevens LA, Nolin TD, Richardson MM, et al. Comparison of drug dos-)]TJ
1.2094 -1.2375 TD
-0.023 Tc
0.023 Tw
(ing recommendations based on measured GFR and kidney function esti-)Tj
-0.0251 Tc
(m)'
0.75294 0.00001 TD
-0.025 Tc
0.013 Tw
[(ating equations. Am J Kidney Dis 2009;54:33)-25(-)-125(42. )]TJ
-1.95229 -1.3625 TD
-0.012 Tc
0.012 Tw
[(8.)-488(Golik MV)130(, Lawrence KR. Comparison of dosing recommendations for)]TJ
1.19935 -1.2375 TD
-0.025 Tc
0.021 Tw
(antimicrobial drugs based on two methods for assessing kidney function:)Tj
T*
-0.001 Tc
0 Tw
[(Cockcroft-Gault and Modification of Diet in Renal Disease. Phar)-25(ma-)]TJ
T*
-0.025 Tc
0.013 Tw
[(cotherapy 2008;28:1)35(125)-25(-)-24(32.)]TJ
-1.19724 -1.3625 TD
-0.01 Tc
0.01 Tw
[(9.)-490(Spruill WJ, W)80(ade WE, Cobb HH 3rd. Continuing the use of the Cock-)]TJ
1.19724 -1.2375 TD
-0.025 Tc
0.007 Tw
(croft-Gault equation for drug dosing in patients with impaired renal func-)Tj
T*
0.013 Tw
[(tion. Clin Phar)-25(macol Ther 2009;86:468)-25(-70.)]TJ
-1.6875 -1.3625 TD
-0.018 Tc
0.018 Tw
[(10.)-482(Gill J, Malyuk R, Djurdjev O, Levin A. Use of GFR equations to adjust)]TJ
1.6875 -1.2375 TD
-0.017 Tc
0.017 Tw
(drug doses in an elderly multi-ethnic group\321a cautionary tale. Nephrol)Tj
0 -1.23749 TD
-0.025 Tc
0.013 Tw
[(Dial T)35(ransplant 2007;22:2894)-75(-99.)]TJ
-1.6875 -1.375 TD
-0.024 Tc
0.024 Tw
[(1)35(1.)-476(Melloni C, Peterson ED, Chen A)90(Y)130(, et al. Cockcroft-Gault versus Modifi-)]TJ
1.6875 -1.25 TD
-0.018 Tc
0.017 Tw
(cation of Diet in Renal Disease: importance of glomerular filtration rate)Tj
T*
-0.023 Tc
0.023 Tw
[(for)-25(mula for classification of chronic kidney disease in patients with non-)]TJ
T*
0 Tc
0 Tw
(ST)Tj
1.07666 0.00001 TD
0.045 Tw
(-segment elevation acute coronary syndromes. J Am Coll Cardiol)Tj
-1.07666 -1.25001 TD
-0.025 Tc
0 Tw
[(2008;51:991)50(-)-75(6.)]TJ
30.625 28.03749 TD
-0.003 Tc
0.003 Tw
[(12.)-497(Roberts GW)90(, Ibsen PM, Schioler CT)75(. Modified Diet in Renal Disease)]TJ
1.6875 -1.25 TD
0 Tc
0 Tw
(method overestimates renal function in selected elderly patients. Age)Tj
T*
-0.025 Tc
0.013 Tw
[(Ageing 2009;38:698)-25(-703.)]TJ
-1.6875 -1.375 TD
0.024 Tw
[(13.)-475(Her)-25(msen ED, Maiefski M, Florescu MC, et al. Comparison of the Modi-)]TJ
1.6875 -1.25 TD
-0.023 Tc
0.023 Tw
(fication of Diet in Renal Disease and Cockcroft-Gault equations for dos-)Tj
T*
-0.025 Tc
0.013 Tw
[(ing antimicrobials. Phar)-25(macotherapy 2009;29:649)-25(-55.)]TJ
-1.6875 -1.375 TD
0.004 Tw
[(14.)-475(P\216quignot R, Belmin J, Chauvelier S, et al. Renal function in older hospi-)]TJ
1.6875 -1.25 TD
-0.014 Tc
0.013 Tw
(tal patients is more accurately estimated using the Cockcroft-Gault for-)Tj
T*
-0.025 Tc
0 Tw
[(mula than the Modification of Diet in Renal Disease for)-25(mula. J Am Geri-)]TJ
T*
0.013 Tw
[(atr Soc 2009;57:1638)-25(-)-125(43.)]TJ
-1.6875 -1.375 TD
-0.014 Tc
0.014 Tw
[(15.)-486(Aktas MK, Shah AH, Akiyama T)75(. Dofetilide-induced long QT and tor)1(-)]TJ
1.6875 -1.25 TD
-0.025 Tc
0.013 Tw
[(sades de pointes. Ann Noninvasive Electrocardiol 2007;12:197-)-25(202.)]TJ
-1.6875 -1.375 TD
-0.02 Tc
0.02 Tw
[(16.)-480(Food and Drug Administration. Guidance for industry: phar)-25(macokinetic)]TJ
1.6875 -1.25 TD
-0.025 Tc
0.017 Tw
(studies in patients with impaired renal function\321study design, data anal-)Tj
T*
0.025 Tw
(ysis, and impact on dosing and labeling. Rockville, MD: US Department)Tj
T*
0.013 Tw
(of Health and Human Services, May 1998.)Tj
-1.6875 -1.375 TD
-0.019 Tc
0.019 Tw
[(17.)-481(Dowling TC, Matzke GR, Murphy JE, Burckart GJ. Evaluation of renal)]TJ
1.6875 -1.25 TD
-0.025 Tc
0.012 Tw
[(drug dosing: prescribing infor)-25(mation and clinical phar)-25(macist approaches.)]TJ
T*
0.013 Tw
[(Phar)-25(macotherapy 2010;30:776)-25(-786.)]TJ
-1.6875 -1.375 TD
-0.009 Tc
0.009 Tw
[(18.)-491(Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate)]TJ
1.6875 -1.25 TD
-0.025 Tc
0.013 Tw
[(glomerular filtration rate. Ann Inter)-25(n Med 2009;150:604)-75(-12.)]TJ
ET
0 0 0 0 k
50.5 14 378.5 14.524 re
f
Q
/GS2 gs
/GS1 gs
q
BT
/F5 1 Tf
5 0 0 5 50.5 23.1856 Tm
0 0 0 1 k
(n)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F4 1 Tf
10 0 0 10 63.6811 21.6856 Tm
0 0 0 1 k
-0.025 Tc
0.013 Tw
[(The Annals of Phar)-25(macotherapy )]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F5 1 Tf
5 0 0 5 196.8061 23.1856 Tm
0 0 0 1 k
(n)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F4 1 Tf
10 0 0 10 209.9871 21.6856 Tm
0 0 0 1 k
-0.025 Tc
0.013 Tw
[(201)75(1 July/August, V)110(olume 45)]TJ
ET
0 0 0 0 k
463 17.694 80.5 10.806 re
f
BT
/F4 1 Tf
10 0 0 10 488.4582 21.6616 Tm
0 0 0 1 k
0 Tw
(theannals.com)Tj
ET
0 0 0 0 k
50.5 740.1929 234 10 re
f
Q
/GS2 gs
/GS1 gs
q
BT
/F19 1 Tf
8 0 0 8 50.5 744.7228 Tm
0 0 0 1 k
-0.013 Tw
[(TH Denetclaw)-238(et al.)]TJ
ET
Q
endstream
endobj
1 0 obj
<>
endobj
2 0 obj
<>
endobj
3 0 obj
<>
endobj
52 0 obj
<>
endobj
16 0 obj
<>
endobj
28 0 obj
<>
endobj
32 0 obj
<>
endobj
31 0 obj
<>
endobj
29 0 obj
<>
endobj
30 0 obj
<>stream
LGUNNQ+ZapfDingbatsITC 6
?
? h e k a73 %<
07YV!ss
endstream
endobj
27 0 obj
<>
endobj
25 0 obj
<>
endobj
26 0 obj
<>stream
FUPYWK+Times-Italic C =m
S }002.001Copyright 1994-1997 Stream Technologies Inc. All Rights Reserved.
Turku is a trademark of Stream Technologies Inc.Turku ItalicTurku ( 5 I F " O B M T P G 1 S N D U Q Z + V H
7 ( J E * L 4 X 3 ' * Y LOE|>+ Z
S
z
v
K
f
PK-v"a.#}YszF{9 ֨rKx*vvOv]p_QvwzepfKFM#-
KL}wBztuj|P)Ʈ}nWS}Wap{ڻby/
oT29&3VղCQk{`Se,J7+Gv{t$dvv+vXS,qA}{b{O\~pgx~P{V(*vvNv`n|UFy4qe,4&H^et[{x~nvl@$ü㱬zlf`7{P|l{*[p~~YSyƅL[od1J-=bѲ{Lqwo3,z!drqqdv;Q{9{rv>"v;}ziyUCwxuvvAv Թ|O}}~|nqcC[aJ-?@[nkaRlz|w4|xًg=|*vYvhU2(*0-/W *<8)Bm
[kp
fPMvx:gXaexdjibu\j#0k39tlX_zsw}zsiqM 0|s{dvŰBz`}v`
={RP{SU, $OWxt{g;vv0xnX@7(^w[WWW{y~ih: аյfӗvv\FxR}ZOxyzgsk24Ha㕱tiO?D8[$vP{z{M8xѼ»||T;,»Ϻ}^ZZ}Qz~o{b5w<aH% '.)Uɮ{cZSk[Sh${|ru|v+B;\Sbib{mBt5uy~rlpj{}*MvWiaBL[l=T0uzpsjN~Y[|b\y}!0=+1( 5'lt(̤ļmWbLvvc>uhv{|wZdP,/p]wNqyvE}VzYlGV~{|tmxqplwww}ptz{upy #*WF-*?Q%g͵ɋWDP`C%etzzrXv~URUU
*H*O(.,|~01&jy=*T]J5_jjvhUjUƬ\<*v-02v{+{xwe0}tK#by"v}{̅oosge|{stwopyujWh-ė*mvNvvo }[Nyy|AarT`HP/XUnq Q}z@}lgYW\pzgxоOhhwlyϯлvAvJZ/AA*Lv¬*jlOzv; 0=/UnpPcyxt}|\gFoGH]j{ؘE}.R5Neuͮr`oMVQa?>XƯroxd$sinvxpz{}rurVgx༶dv4vDN{uy|hfK^IJɒ{9*vEKqr:c5CwGZGE,,i*#/#n|yoT?!9'5tzoo}zs{zsjtȋ=0F,z$rmlrrlmryezʆshfyolwe|S?=ZR!Y|~uyofK@gVZk8 EܡOΐv;vpovtmmtn~j]jlyֈH~sF{y{yd$lrex*v;PwByvrg_3zb ,`B^еevum{]Vwy|{" D4dtouaѠv"v{ƅn}pvP|US{T~PĔѠvT}o}Loр|rmlrrlmr'rmlrrlmrbvvBvSa2K{}h2 rw
ZM}uC{nu+HAͪYֱ}hPzryL?**yvv0ty~yfz>DD*PrQq]@SQB9K蒋wjsft/8{ȶ^ v`vv:Hvjt}|xjf]_I&kSz[zV}tm#4f:Ѝq=]dvuC{bnwO{QTzT~eˆ(_xw."&KU soyصdFdvۮ"{υn}ptO{RR{QysŊYx|sxZ,B}͋,~M}xxAgs
_
endstream
endobj
15 0 obj
<>
endobj
13 0 obj
<>
endobj
14 0 obj
<>stream
RMZUAK+Times-Roman @